Treatment of Elevated Arterial Pulmonary Pressure With Inhaled Iloprost

This study is currently recruiting participants.

Verified by Lund University Hospital, September 2007

Sponsors and Collaborators:	Lund University Hospital Bayer
Information provided by:	Lund University Hospital
ClinicalTrials.gov Identifier:	NCT00216931

Purpose

The purpose of this study is to determine if iloprost is effective in the treatment of elevated arterial pulmonary pressure in children with ventilator treated respiratory distress syndrome.

Condition	Intervention
Persistent Pulmonary Hypertension Respiratory Distress Syndrome	Drug: iloprost

Genetics Home Reference related topics: pulmonary arterial hypertension

MedlinePlus related topics: High Blood Pressure Pulmonary Hypertension

Drug Information available for: Iloprost

U.S. FDA Resources

Study Type:	Interventional
Study Design:	Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Official Title:	Treatment of Elevated Arterial Pulmonary Pressure With Inhaled Iloprost

Further study details as provided by Lund University Hospital:

Primary Outcome Measures:

Oxygenation index
Cardiac output

Estimated Enrollment:	40
Study Start Date:	May 2006
Estimated Study Completion Date:	October 2008

Eligibility

Ages Eligible for Study:	up to 48 Hours
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Elevated arterial pulmonary pressure
GA > 24 GW
24-48 hours of age
Ventilator treatment

Exclusion Criteria:

Congenital anomalies
Severe hypotension

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00216931

Contacts

Contact: Vineta Fellman, Professor

+46 46 172698

Vineta.Fellman@med.lu.se

Locations

Sweden
University Hospital in Lund , Department of Pediatrics	Recruiting
Lund, Sweden, 221 85
Contact: Anders Nordh, MD +46 46178446 anders.nordh@skane.se
Principal Investigator: Anders Nordh, MD

Sponsors and Collaborators

Lund University Hospital

Bayer

Investigators

Principal Investigator:

Vineta Fellman, Professor

Lund University Hospital, Department of Pediatrics

More Information

Study ID Numbers:	2004-001551-11
Study First Received:	September 15, 2005
Last Updated:	December 10, 2007
ClinicalTrials.gov Identifier:	NCT00216931
Health Authority:	Sweden: Medical Products Agency

Study placed in the following topic categories:

Iloprost
Respiratory Tract Diseases
Hypertension, Pulmonary
Lung Diseases
Respiration Disorders

Respiratory Distress Syndrome, Adult
Vascular Diseases
Acute respiratory distress syndrome
Hypertension

Additional relevant MeSH terms:

Vasodilator Agents
Pathologic Processes
Disease
Therapeutic Uses
Syndrome

Hematologic Agents
Platelet Aggregation Inhibitors
Cardiovascular Diseases
Cardiovascular Agents
Pharmacologic Actions

ClinicalTrials.gov processed this record on January 14, 2009